RecruitingNot ApplicableNCT06223633

PK(Pharmacokinetic) Papyrus Covered Coronary Stent System


Sponsor

Methodist Health System

Enrollment

41 participants

Start Date

Aug 10, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The PK Papyrus Covered Coronary Stent System is a coronary stent being used at Methodist Dallas Medical Center for patients with coronary perforations.


Eligibility

Inclusion Criteria1

  • Patients with acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter

Exclusion Criteria7

  • Patients in whom antiplatelet agents or anticoagulation therapy is contraindicated.
  • Patients with a known allergy or hypersensitivity to amorphous silicon carbide or any other compound of the system (siloxane-based polyurethane, L-605 cobalt chromium alloy including tungsten and nickel).
  • Lesions that cannot be reached or treated with the system.
  • Lesions with threatened or abrupt closure during attempted pre-dilation prior to stent implantation.
  • Risk of treatment-related occlusion of vital coronary artery side branches.
  • Uncorrected bleeding disorders.
  • Allergy to contrast media.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPK Papyrus Covered Coronary Stent System

PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.


Locations(1)

Methodist Dallas Medical Center

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06223633


Related Trials